Haemorrhagic transformation in acute ischaemic stroke following thrombolysis therapy: Classification, pathogenesis and risk factors

Postgraduate Medical Journal

Volumn 84, Issue 993, 2008, Pages 361-367

  Thanvi, B R ^a   Treadwell, S ^b   Robinson, T ^b  

^a SOUTH WARWICKSHIRE NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY HOSPITALS OF LEICESTER NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; DESMOTEPLASE; DISUFENTON SODIUM; FIBRINOLYTIC AGENT; PLACEBO; PROUROKINASE; RECOMBINANT PLASMINOGEN ACTIVATOR; STREPTOKINASE; TENECTEPLASE; UROKINASE;

BLOOD BRAIN BARRIER; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; CLINICAL FEATURE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DISEASE CLASSIFICATION; DISEASE COURSE; DRUG HALF LIFE; EMBOLECTOMY; FIBRINOLYTIC THERAPY; HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; PROGNOSIS; REVIEW; RISK FACTOR; TREATMENT OUTCOME;

CEREBRAL HEMORRHAGE; CEREBRAL INFARCTION; HUMANS; PROGNOSIS; RISK FACTORS; STROKE; THROMBOLYTIC THERAPY;

EID: 50249187264     PISSN: 00325473     EISSN: None     Source Type: Journal    
DOI: 10.1136/pgmj.2007.067058     Document Type: Review

References (78)

1. Teal PA, Pessin MS. Hemorrhagic transformation. The spectrum of ischemia-related brain hemorrhage. Neurosurg Clin N Am 1992;3:601-10.
2. Hanaway J, Torack R, Fletcher AP, et al. Intracranial bleeding associated with urokinase therapy for acute ischaemic hemispherical stroke. Stroke 1976;7:143-146.
3. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke. Stroke 1997;28:2109-18.
4. Kase CS, Furlan AJ, Wechsler LR, et al. Cerebral haemorrhage after intra-arterial thrombolysis for ischemic stroke: the PROACT II trial. Neurology 2001;57:1603-10.
5. Larrue V, von Kummer R, del Zoppo G, et al. Hemorrhagic transformation in acute ischemic stroke. Potential contributing factors in the European Cooperative Acute Stroke Study. Stroke 1997;28:957-60.
6. von Kummar R. Brain haemorrhage after thrombolysis: good or bad? Stroke 2002;33:1446-7.
7. Fiorelli M, Bastianello S, von Kummer R, et al. Hemorrhagic transformation within 36 hours of a cerebral infarct: relationships with early clinical deterioration and 3-month outcome in the European Cooperative Acute Stroke Study I (ECASS I) cohort. Stroke 1999;30:2280-4.
8. Berger C, Fiorelli M, Steiner T, et al. Hemorrhagic transformation of ischemic brain tissue: asymptomatic or symptomatic? Stroke 2001;32:1330-5.
9. Libman R, Kwiatkowski T. Asymptomatic hemorrhage after thrombolysis may not be benign: prognosis by hemorrhage type of the Canadian alteplase for stroke effectiveness study registry. Stroke 2007;38:e88.
10. Arnould MC, Grandin CB, Peeters A, et al. Comparison of CT and three MR sequences for detecting and categorizing early (48 hours) hemorrhagic transformation in hyperacute ischemic stroke. Am J Neuroradiol 2004;25:939-44.
11. Hornig CR, Dorndorf W, Agnoli AL. Haemorrhagic cerebral infarction - a prospective study. Stroke 1986;17:179-55.
12. Jorgensen L, Torvik A. Ischaemic cerebrovascular diseases in an autopsy series, 2: prevalence, location, pathogenesis, and clinical course of cerebral infarcts. J Neurol Sci 1969;9:285-320.
13. Pessin MS, Del Zoppo GJ, Estol CJ. Thrombolytic agents in the treatment of stroke. Clin Neuropharmacol 1990;13:271-89.
14. Fisher CM, Adams RD. Observations on brain embolism with special reference to the mechanism of haemorrhagic infarction. J Neuropath Exp Neurol 1951;10:92-3.
15. Leonard AD, Newburg S. Cardioembolic stroke. J Neurosci Nurs 1992;24:69-76.
16. Yamaguchi T, Minematsu K, Choki Jl, et al. Clinical and neuroradiological analysis of thrombotic and embolic cerebral function. Jap Circ J 1984;48:50-8.
17. Hacks W, Donnan G, Fieschi C, et al. ATLANTIS Trials Investigators, ECASS Trials Investigators, NINDS rt-PA Study Group Investigators. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet 2004;363:768-74.
18. Ringleb PA, Schwark C, Kohrmann M, et al. Thrombolytic therapy for acute ischaemic stroke in octogenarians: selection by magnetic resonance imaging improves safety but does not improve outcome. J Neurol Neurosurg Psychiatry 2007;78:690-3.
19. Engerter ST, Bonati LH, Lyrer PA. Intravenous thrombolysis in stroke patients of > or = 80 versus <80 years of age - a systematic review across cohort studies. Age Ageing 2006;35:572-80.
20. Berrouschot J, Rother J, Glahn J, et a/. Outcome and severe hemorrhagic complications of intravenous thrombolysis with tissue plasminogen old (> or =80 years) stroke patients. Stroke 2005;36:2421-5.
21. del Zoppo GJ, von Kummer R, Hamann GF. Ischaemic damage of brain microvessels: inherent risks for thrombolytic treatment in stroke. J Neurol Neurosurg Psychiatry 1998;65:1-9.
22. Wang X, Lo EH. Triggers and mediators of haemorrhagic transformation in cerebral ischaemia. Mol Neurobiol 2003;28:229- 44.
23. Burggraf D, Trinkl A, Burk J, et al. Vascular integral immunoreactivity is selectively lost on capillaries during rat focal cerebral ischemia and reperfusion. Brain Res 2008;1188:189-97.
24. Wagner S, Tagaya M, Koziol JA, et al. Rapid disruption of an astrocyte interaction with the extracellular matrix mediated by integral alpha 6 beta 4 during focal cerebral ischemia/reperfusion. Stroke 1997;28:858-65.
25. Ogata J, Yutani C, Imakita M, et al. Haemorrhagic infarct of the brain without a reopening of the occluded arteries in cardioembolic stroke. Stroke 1989;20:876-83.
26. Saku Y, Choki J, Waki R, et al. Haemorrhagic infarct induced by arterial hypertension in cat brain following middle cerebral artery occlusion. Stroke 1990;21:589-95.
27. Trouillas P, von Kummer R. Classification and pathogenesis ri cerebral hemorrhages after thrombolysis in ischemic stroke. Stroke 2006;37:556-61.
28. Kase CK, Pessin MS, Zivin JA, et al. Intracranial hemorrhage after coronary thrombolysis with tissue plasminogen activator. JAMA 1992;92:384-90.
29. Trouillas P, Derex L, Philippeau F, et al. Early fibrinogen degradation coagulopathy is predictive of parenchymal hematomas in cerebral rt-PA thromborysis: a study of 157 cases. Stroke 2004;35:1323-8.
30. Castellanos M, Lara R, Serena J, et al. Plasma metalloproteinase-9 concentration predicts haemorrhagic transformation in acute ischaemic stroke. Stroke 2003;34:40-6.
31. Montaner J, Molina CA, Monasterio J, et al. Matrix metallopfoteinase-9 pretreatment level predicts intracranial hemorrhagic complications after thromborysis in human stroke. Circulation 2003;107:598-603.
32. Shuaib A, Lees KR, Lyden P, et al. SAINT II Trial Investigators. NXY-059 for the treatment of acute ischemic stroke.N Engl J Med 2007;357:562-71.
33. Furlan A, Higashida R, Wechsler L et al. Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism. JAMA 1999;282:2003-11.
34. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995;333:1581-7.
35. Smith WS, Sung G, Starkman S. et al. MERCI Trial Investigators. Safety and efficacy of mechanical embotectomy in acute ischemic stroke: results of the MERCI trial. Stroke 2005;36:1432-8.
36. Multicenter Acute Stroke Trial-Europe Study Group Thrombolytic therapy with streptokinase in acute ischemic stroke. N Engl J Med 1996;335:145-50.
37. Morris AD, Ritchie C, Grosset DG, et a/. A pilot study of streptokinase for acute cerebral infarction. Q J M 1995;88:727-31.
38. Donnan GA, Davis SM, Chambers BR, et al, for the Australian Streptokinase (ASK) Trial Study Group. Streptokinase for acute ischemic stroke with relationship to time of administration. JAMA 1996;276:961-6.
39. The Internet Stroke Centre. OIAS-2 desmoteplase in acute ischemic stroke. http:// www.Strokecenter.Org/trials/trialdetail.Aspx?Tid = 515, 2007.
40. Haley EC Jr, Lyden PD, Johnston KC. et al, TNK in Stroke Investigators. A plot doseescalation safety study of tenecteotase in acute ischemic stroke. Stroke 2005;36:607-12.
41. Hacke W, Albers G, Al-Rawi Y. et al, DIAS Study Group. The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): a phase II MRI-based 9-hour window acute stroke thromborysis trial with intravenous desmoteplase. Stroke 2005;36:66-73.
42. Levy DE, Brott TG, Haley EC Jr. et al. Factors related to intracranial hematoma formation in patients receiving tissue-type plasminogen activator for acute ischemic stroke. Stroke 1994;25:291-7.
43. Smith WS. Safety of mechanical thrombectomy and intravenous tissue plasminogen activator in acute ischemic stroke. Results of the mufti Mechanical Embolus Removal in Cerebral Ischemia (MERCI) trial, part I. AJNR Am J Neuroradiol 2006;27:1177-82.
44. Hill MD, Buchan AM, Canadian Alteplase for Stroke Effectiveness Study (CASES) Investigators. Thrombolysis for acute ischemic stroke: results of the Canadian Alteplase for Stroke Effectiveness Study. Can Med Assoc J 2005;172:1307-12.
45. Molina CA, Afvarez-Sabin J, Montaner J, et al. Thrombolysrs-related hemorrhagic infarction: a marker of early reperfusion, reduced infarct size, and improved outcome in patients with proximal middle cerebral artery occlusion. Stroke 2002;33:1551-6.
46. Molina CA, Montaner J, Abilleira S. Timing of spontaneous recanalization and risk of hemorrhagic transformation in acute cardioembolic stroke. Stroke 2001;32:1079-84.
47. Larrue V, von Kummer RR, Muter A. et a/. Risk factors for severe hemorrhagic transformation in ischemic stroke patients treated with recombinant tissue plasminogen activator: a secondary analysis of the European-Australasian Acute Stroke Study (ECASS II). Stroke 2001;32:438-41.
48. TanneD. Kasner SE, Demchuk AM, et al. Markers of increased risk of intracerebral hemorrhage after intravenous recombinant tissue plasminogen activator therapy for acute ischemic stroke in clinical practice: the Multicenter rt-PA Stroke Survey. Circulation 2002;105:1679-85.
49. Kim D, Ford GA, KktweH CS, et al. UCLA Intra-Arterial Thrombolysis Investigators. Intra-arteri al thrombolysis for acute stroke in patients 80 and older: a comparison of results in patients younger than 80 years. AJNR Am J Neuroradiol 2007;28:159-63.
50. Cocho D, Borrell M, Martí-Fàbregas J. et al. Pretreatment hemostatic markers of symptomatic intracerebral hemorrhage in patients treated with tissue plasminogen activator. Stroke 2006;37:996-9.
51. Patel SC, Levine SR, Tilley BC, et al. National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Lack of clinical significance of early ischemic changes on computed tomography in acute stroke. JAMA 2001;286:2830-8.
52. Tong DC, Yenari MA, Albers GW, et al. Correlation of perfusion- and diffusion-weighted MRI with NIHSS score in acute (<6.5 hour) ischemic stroke. Neurology 1998;50:864-70.
53. Jaillard A, Comu C, Durieux A, et al. Hemorrhagic transformation in acute ischemic stroke. The MAST-E study. Stroke 1999;30:1326-32.
54. Kakuda W, Thijs VN, Lansberg MG, et al. DEFUSE Investigators. Clinical importance of microbleeds in patients receiving IV thrombolysis. Neurology 2005;65:1175-8.
55. Bowes MP, Zivin JA, Thomas GR, et al. Acute hypertension, but not thrombolysis, increases the incidence and severity of hemorrhagic transformation following experimental stroke in rabbits. Exp Neurol 1996;141:40-6.
56. Brott TC, Haley EC, Levy DE, et al. Urgent therapy for stroke, part I: pilot study of tissue plasminogen activator administered within 90 minutes from onset. Stroke 1992;23:632-40.
57. Haley EC, Levy DE, Brott TC, et al. Urgent therapy for stroke, part II: pilot study of tissue plasminogen activator administered within 90-180 minutes from onset. Stroke 1992;23:641-5.
58. Gore JM, Granger CB, Simoons ML, et al. Stroke after thrombolysis. Mortality and functional outcomes in the GUSTO-I trial. Global Use of Strategies to Open Occluded Coronary Arteries. Circulation 1995;92:2811-8.
59. Lansberg MG, Albers GW, Wijman CA. Symptomatic intracerebral hemorrhage following thrombolytic therapy for acute ischemic stroke: a review of the risk factors. Cerebrovasc Dis 2007;24:1-10.
60. Gilligan AK, Markus R, Read S, et al. Australian Streptokinase Trial Investigators. Baseline blood pressure but not early computed tomography changes predict major hemorrhage after streptokinase in acute ischemic stroke. Stroke 2002;33:2236-42.
61. Levy DE, Brott TG, Haley EC Jr, et al. Factors related to intracranial hematoma formation in patients receiving tissue-type plasminogen activator for acute ischemic stroke. Stroke 1994;25:291-7.
62. Ciccone A, Motto C, Aritzu E, et al. Negative interaction of aspirin and streptokinase in acute ischemic stroke: further analysis of the Multicenter Acute Stroke Trial-Italy. Cerebrovasc Dis 2000;10:61-4.
63. Derex L, Hermier M, Adleleine P, et al. Clinical and imaging predictors of intracerebral hemorrhage in stroke patients treated with intravenous tissue plasminogen activator. J Neurol Neurosurg Psychiatry 2005;76:70-5.
64. International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. Lancet 1997;349:1569-81.
65. Ribo M, Montaner J, Molina CA, et al. Admission fibrinolytic profile is associated with symptomatic hemorrhagic transformation in stroke patients treated with tissue plasminogen activator. Stroke 2004;35:2123-7.
66. Foerch C, Wunderlich MT, Dvorak F, et al. Elevated serum S100B levels indicate a higher risk of hemorrhagic transformation after thrombolytic therapy in acute stroke Stroke 2007;38:2491-5.
67. Dubey N, Bakshi R, Wasay M, et al. Early computed tomography hypodensity predicts hemorrhage after intravenous tissue plasminogen activator in acute ischemic stroke. J Neuroimaging 2001;11:184-8.
68. Hacke W, Kaste M, Fieschi C, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA 1995;274:1017-25.
69. Selim M, Fink JN, Kumar S, et al. Predictors of hemorrhagic transformation after intravenous recombinant tissue plasminogen activator: prognostic value of the initial apparent diffusion coefficient and diffusion-weighted lesion volume. Stroke 2002;33:2047-52.
70. Alsop DC, Makovetskaya E, Kumar S, et al. Markedly reduced apparent blood volume on bolus contrast magnetic resonance imaging as a predictor of hemorrhage after thrombolytic therapy for acute ischemic stroke. Stroke 2005;36:746-50.
71. Warach S, Latour LL. Evidence of reperfusion injury, exacerbated by thrombolytic therapy, in human focal brain ischemia using a novel imaging marker of early blood-brain barrier disruption. Stroke 2004;35(11 Suppl 1):2659-61.
72. Kim EY, Na DG, Kim SS, et al. Prediction of hemorrhagic transformation in acute ischemic stroke: role of diffusion-weighted imaging and early parenchymal enhancement. Am J Neumradiol 2005;26:1050-5.
73. Kakuda W, Thijs VN, Lansberg MG, et al. DEFUSE Investigators. Clinical importance of microbleeds in patients receiving IV thrombolysis. Neurology 2005;65:1175-8.
74. Derex L, Nighoghossian N, Hermier M, et al. Thrombolysis for ischemic stroke in patients with old microbleeds on pretreatment MRI. Cerebrovasc Dis 2004;17:238-41.
75. Fiehler J, Albers GW, Boulanger JM, et al, the MR STROKE Group. Bleeding risk analysis in stroke imaging before thromboLysis (BRASIL): pooled analysis of T2*-weighted magnetic resonance imaging data from 570 patients. Stroke 2007;38:2738-44.
76. Derex L, Nighoghossian N. lntracerebralhaemorrhageafterthrombolysisforacuteischemic stroke. An update. J Neurol Neurosurg Psychiatry 2008;Jan 25 [epub ahead of print).
77. Fiehler J, Remmele C, Kucinski T, et al. Reperfusion after severe local perfusion deficit precedes haemorrhagic transformation: an MRI study in acute stroke patients. Cerebrovasc Dis 2005;19:117-24.
78. Kim D, Ford GA, Kidwell CS, et al, UCLA Intra-Arterial Thrombolysis Investigators. Intra-arterial thrombolysis for acute stroke in patients 80 and older: a comparison of results in patients younger than 80 years. AJNR Am J Neumradiol 2007;28:159-63.